Coenzyme Q10 Oiling Composition to Prevent Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Coenzyme Q10 in existing products is prone to crystallization, leading to poor solubility and bioavailability, necessitating high doses for efficacy and limiting its application in cosmetics and health care products.
Innovation Solution
A method involving two-stage grinding of Coenzyme Q10 crystals to a specific particle size range (50-120 nm) using a combination of saturated and unsaturated fatty acid esters and a biphase emulsifying agent under negative pressure, ensuring the Coenzyme Q10 remains in a molecular form, enhancing solubility and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If coenzyme Q10 is dissolved in single plant oil as auxiliary dissolving oiling agent, then the coenzyme Q10 can be diluted and dissolved, but the coenzyme Q10 has no good effect due to its limited dissolubility in oil and a crystalline state
Solution Approach 1:
The patent uses a composite oiling agent system comprising multiple plant oils (soybean oil, corn oil, sunflower seed oil) combined with specific auxiliary dissolving agents (polyethylene glycol, propylene glycol, glycerol). This composite approach overcomes the limited dissolubility of coenzyme Q10 in single plant oils by creating a multi-phase solvent system that maintains coenzyme Q10 in molecular form rather than crystalline state, thereby improving both dissolubility and bioavailability
Solution Approach 2:
The patent changes the physical-chemical parameters of the oiling agent system by introducing auxiliary dissolving agents with different molecular weights and hydrophilic-lipophilic balance properties. Specifically, it uses polyethylene glycol with molecular weight of 200-400, propylene glycol, and glycerol in controlled proportions to alter the solvent characteristics, enabling coenzyme Q10 to remain in molecular form at lower temperatures and improve its dissolution and absorption characteristics
2Stability of the object's composition
If coenzyme Q10 is present in a crystal state, then it can be stored stably, but it is extremely poor in water solubility, low in bioavailability in a human body, and a large number of coenzyme Q10 needs to be supplemented to achieve the expected effect
Solution Approach 1:
The patent utilizes phase transition principles by controlling the temperature and composition of the oiling agent system to maintain coenzyme Q10 in a molecular (amorphous) state rather than allowing it to crystallize. The specific formulation with polyethylene glycol, propylene glycol, and glycerol creates a eutectic system that lowers the freezing point and prevents crystallization at storage temperatures, thereby maintaining high bioavailability while achieving long-term stability through proper phase control
Solution Approach 2:
The patent introduces auxiliary dissolving agents (polyethylene glycol, propylene glycol, glycerol) as intermediary substances that mediate between the hydrophobic coenzyme Q10 and the aqueous environment. These intermediaries form a bridge that enhances the solubility and bioavailability of coenzyme Q10 without requiring it to be in crystalline form, allowing for better absorption while maintaining stability through the protective micellar structure
3Manufacturing precision
If the particle size of coenzyme Q10 crystals is reduced to facilitate dissolution, then the dissolution into solvent is facilitated, but the finer the particle size is not the better, and the dissolution effect is obviously worsen when particle size is further reduced
Solution Approach 1:
The patent optimizes the particle size parameter of coenzyme Q10 to a specific range (50-120 nm) rather than simply minimizing it. This precise parameter control, combined with the use of auxiliary dissolving agents, creates an optimal balance between surface area for dissolution and prevention of excessive aggregation. The specific particle size range maximizes dissolution effect while avoiding the worsening that occurs with ultra-fine particles
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a Coenzyme Q10 oiling agent with high content, stable molecular form, and improved bioavailability, preventing crystallization and precipitation, suitable for various applications.
Implementation Method 1
dissolved under the negative pressure under the combined action of the mixed oil and the biphase emulsifying agent
Implementation Method 2
the use of the biphase emulsifying agent can endow the coenzyme Q10 with hydrophilicity and lipophilicity
Implementation Method 3
dissolved in the molecular form below a melting temperature
Implementation Method 4
grinding coenzyme Q10 crystals in a presence of an oil mixture I and a biphase emulsifying agent to reduce a particle size D50 of the coenzyme Q10 crystals to 50-120 nm
Implementation Method 5
the coenzyme Q10 can be stably dispersed into water and oil systems
Implementation Method 6
the coenzyme Q10 in the coenzyme Q10 oiling agent is present in a molecular form
Data Source
AI summary
The present disclosure belongs to the technical field of coenzyme Q10, and relates to a method of preparing a coenzyme Q10 oiling agent, comprising: grinding coenzyme Q10 crystals in a presence of an oil mixture I and a biphase emulsifying agent to reduce a particle size D50 of the coenzyme Q10 crystals to 50-120 nm, and then evenly mixing an obtained fine grinding fluid with an oil mixture II under a negative pressure to obtain the coenzyme Q10 oiling agent, wherein both the oil mixture I and the oil mixture II contain the mixed oil. The coenzyme Q10 in the coenzyme Q10 oiling agent provided by the present disclosure still can be stably present in the molecular form at high content, and therefore has high bioavailability.